Two fresh blood samples collected with EDTA were distributed by courier in December 2014 to 206 Italian laboratories asking for the determination of their HbA1c concentrations. Target HbA1c values were assigned by the IFCC reference measurement procedure based on HPLCcapillary electrophoresis. The results, collected from 193 laboratories using analytical systems mainly from five manufacturers (Bio-Rad Laboratories, A. Menarini Diagnostics, Roche Diagnostics, Sebia and Tosoh), showed a global variability (in terms of CV) of 5.3% and 3.8% at HbA1c values of 37.4 mmol/mol (sample 1) and 62.0 mmol/mol (sample 2), respectively. Globally, 84% of the participants reported HbA1c results within the total allowable error (TE) of 8.6% (sample 1) and 93% for sample 2. These percentages decreased to 70% and 77%, respectively, when using a goal for the allowable TE of 6.0% as criterion. Inter-laboratory CVs, calculated per group of methods, were between 3.3% and 5.0% and between 2.2% and 3.7% for sample 1 and 2, respectively. Tosoh users registered the smaller inter-laboratory CV in sample 1 and Sebia's in sample 2. With regard to trueness, all methods had a mean bias ≤2.8% respect to the target values, with the exception of Tosoh (bias of +6.1% and +5.8%, for samples 1 and 2, respectively).

Il progetto pilota SIBioC di VEQ della misura dell'emoglobina glicata = Pilot SIBioC EQAS project on glycated hemoglobin measurement / A. Mosca, R. Paleari, A. Carobene, F. Ceriotti. - In: BIOCHIMICA CLINICA. - ISSN 0393-0564. - 39:6(2015), pp. 568-574.

Il progetto pilota SIBioC di VEQ della misura dell'emoglobina glicata = Pilot SIBioC EQAS project on glycated hemoglobin measurement

A. Mosca
;
R. Paleari;
2015

Abstract

Two fresh blood samples collected with EDTA were distributed by courier in December 2014 to 206 Italian laboratories asking for the determination of their HbA1c concentrations. Target HbA1c values were assigned by the IFCC reference measurement procedure based on HPLCcapillary electrophoresis. The results, collected from 193 laboratories using analytical systems mainly from five manufacturers (Bio-Rad Laboratories, A. Menarini Diagnostics, Roche Diagnostics, Sebia and Tosoh), showed a global variability (in terms of CV) of 5.3% and 3.8% at HbA1c values of 37.4 mmol/mol (sample 1) and 62.0 mmol/mol (sample 2), respectively. Globally, 84% of the participants reported HbA1c results within the total allowable error (TE) of 8.6% (sample 1) and 93% for sample 2. These percentages decreased to 70% and 77%, respectively, when using a goal for the allowable TE of 6.0% as criterion. Inter-laboratory CVs, calculated per group of methods, were between 3.3% and 5.0% and between 2.2% and 3.7% for sample 1 and 2, respectively. Tosoh users registered the smaller inter-laboratory CV in sample 1 and Sebia's in sample 2. With regard to trueness, all methods had a mean bias ≤2.8% respect to the target values, with the exception of Tosoh (bias of +6.1% and +5.8%, for samples 1 and 2, respectively).
clinical biochemistry; medical laboratory technology; biochemistry (medical)
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
2015
http://www.sibioc.it/bc/download/articolo/1139
Article (author)
File in questo prodotto:
File Dimensione Formato  
B_26_VEQ_SIBioC.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.8 MB
Formato Adobe PDF
1.8 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/560759
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact